Evidence Level
Vitamin B1 (Thiamine) is essential for energy metabolism and neurological function. Stracke et al. (2008) demonstrated that benfotiamine, a thiamine analog, at 300 mg/day significantly improved neuropathy symptoms in patients with type 1 and type 2 diabetes, highlighting its potential in managing diabetic complications. Whitfield et al. (2018) underscored the underdiagnosis of thiamine deficiency globally, particularly among high-risk populations such as alcoholics, elderly individuals, and heart failure patients, emphasizing the need for better diagnostic strategies and public health interventions.
Schoenenberger et al. (2012) conducted a randomized, double-blind, placebo-controlled pilot study showing that thiamine supplementation improved left ventricular ejection fraction in heart failure patients with thiamine deficiency, suggesting its role in cardiovascular management. Additionally, Manzardo et al. (2015) found that benfotiamine treatment reduced psychiatric symptoms in males with high lifetime alcoholism severity, while Manzardo et al. (2013) demonstrated that benfotiamine supplementation significantly reduced alcohol consumption in women with severe alcohol dependence compared to placebo. These studies highlight the potential of thiamine analogs in addressing both neurological and behavioral aspects of chronic alcohol use.
Overall, these findings emphasize the importance of thiamine in maintaining neurological health and its therapeutic potential across various clinical conditions.